ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

被引：265

作者：

Hicks, Rodney J. ^{[1
]}

Kwekkeboom, Dik J. ^{[2
]}

Krenning, Eric ^{[3
]}

Bodei, Lisa ^{[4
]}

Grozinsky-Glasberg, Simona ^{[5
]}

Arnold, Rudolf

Borbath, Ivan ^{[6
]}

Cwikla, Jaroslaw ^{[7
]}

Toumpanakis, Christos ^{[8
]}

Kaltsas, Greg ^{[9
]}

Davies, Philippa ^{[8
]}

Hoersch, Dieter ^{[10
]}

Tiensuu Janson, Eva ^{[11
]}

Ramage, John ^{[12
]}

机构：

[1] Peter MacCallum Canc Ctr, Canc Imaging & Neuroendocrine Serv, 305 Grattan St, Melbourne, Vic 3000, Australia

[2] Erasmus MC, ENETS Ctr Excellence Rotterdam, Div Nucl Med, Dept Internal Med, Rotterdam, Netherlands

[3] Erasmus MC, Cyclotron Rotterdam BV, Rotterdam, Netherlands

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Hadassah Hebrew Univ, Med Ctr, Neuroendocrine Tumor Unit, Endocrinol & Metab Serv,Dept Med, Jerusalem, Israel

[6] Clin Univ St Luc, Serv Gastroenterol, Brussels, Belgium

[7] Univ Warmia & Mazury, Dept Radiol, Fac Med Sci, Olsztyn, Poland

[8] Royal Free Hosp, Neuroendocrine Tumour Unit, London, England

[9] Natl Univ Athens, Div Endocrinol, Dept Pathophysiol, Athens, Greece

[10] Gastroenterol & Endocrinol Ctr Neuroendocrine Tum, Bad Berka, Germany

[11] Uppsala Univ Hosp, Dept Endocrine Oncol, Uppsala, Sweden

[12] Hampshire Hosp NHS Trust, Gastroenterol Dept, Basingstoke, Hants, England

来源：

NEUROENDOCRINOLOGY | 2017年 / 105卷 / 03期

关键词：

Radiolabelled somatostatin analogues; Gastroenteropancreatic neuroendocrine tumour; Neuroendocrine tumour; Peptide receptor radionuclide therapy; CHEMORADIONUCLIDE THERAPY; PHASE-I; RADIOPEPTIDE LU-177-OCTREOTATE; TYR(3) OCTREOTATE; LIVER METASTASES; PREDICTIVE-VALUE; F-18-FDG PET; TUMORS; SURVIVAL; Y-90;

D O I：

10.1159/000475526

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish Lu-177-DOTA-octreotate (LutaThera (R)) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies. (C) 2017 S. Karger AG, Basel

引用

页码：295 / 309

页数：15

共 93 条

[81] A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas [J].

Tang, Laura H. ;

Basturk, Olca ;

Sue, Jillian J. ;

Klimstra, David S. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2016, 40 (09) :1192-1202

[82] Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function [J].

Teunissen, Jaap J. M. ;

Krenning, Eric P. ;

de Jong, Frank H. ;

de Rijke, Yolanda B. ;

Feelders, Richard A. ;

van Aken, Maarten O. ;

de Herder, Wouter W. ;

Kwekkeboom, Dik J. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (11) :1758-1766

[83] Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced [J].

Valkema, R ;

Pauwels, S ;

Kvols, LK ;

Barone, R ;

Jamar, F ;

Bakker, WH ;

Kwekkeboom, DJ ;

Bouterfa, H ;

Krenning, EP .

SEMINARS IN NUCLEAR MEDICINE, 2006, 36 (02) :147-156

[84]

Valkema R, 2005, J NUCL MED, V46, p83S

[85] Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide:: The Rotterdam experience [J].

Valkema, R ;

de Jong, M ;

Bakker, WH ;

Breeman, WAP ;

Kooij, PPM ;

Lugtenburg, PJ ;

de Jong, FH ;

Christiansen, A ;

Kam, BLR ;

de Herder, WW ;

Stridsberg, M ;

Lindemans, J ;

Ensing, G ;

Krenning, EP .

SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (02) :110-122

[86] Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours [J].

van Essen, Martijn ;

Krenning, Eric P. ;

Kam, Boen L. ;

de Herder, Wouter W. ;

van Aken, Maarten O. ;

Kwekkeboom, Dik J. .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (04) :743-748

[87] Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate [J].

van Vliet, Esther I. ;

van Eijck, Casper H. ;

de Krijger, Ronald R. ;

van Dijkum, Elisabeth J. Nieveen ;

Teunissen, Jaap J. ;

Kam, Boen L. ;

de Herder, Wouter W. ;

Feelders, Richard A. ;

Bonsing, Bert A. ;

Brabander, Tessa ;

Krenning, Eric P. ;

Kwekkeboom, Dik J. .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1647-1653

[88] Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers [J].

Villard, Linda ;

Romer, Anna ;

Marincek, Nicolas ;

Brunner, Philippe ;

Koller, Michael T. ;

Schindler, Christian ;

Ng, Quinn K. T. ;

Maecke, Helmut R. ;

Mueller-Brand, Jan ;

Rochlitz, Christoph ;

Briel, Matthias ;

Walter, Martin A. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1100-1106

[89]

Waldherr C, 2002, J NUCL MED, V43, P610

[90] The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:: A clinical phase II study [J].

Waldherr, C ;

Pless, M ;

Maecke, HR ;

Haldemann, A ;

Mueller-Brand, J .

ANNALS OF ONCOLOGY, 2001, 12 (07) :941-945

← 1 2 3 4 5 6 7 8 9 10 →